by FMR Global | Dec 15, 2022 | FMR GLOBAL
Clinical trial has received regulatory approval and involves endometriosis candidate SN132D
by FMR Global | Dec 15, 2022 | FMR GLOBAL
Phase 3 clinical trial focuses on adults with moderate-to-severe chronic hand eczema
by FMR Global | Dec 15, 2022 | FMR GLOBAL
Partnership aims to progress personalised cancer therapy by incorporating doggybone DNA
by FMR Global | Dec 15, 2022 | FMR GLOBAL
Data reinforces potential to deliver new standards across HER2-targetable breast cancer
by FMR Global | Dec 15, 2022 | FMR GLOBAL
Implantable ARC therapy demonstrates potential to improve blood pressure regulation
by FMR Global | Dec 15, 2022 | FMR GLOBAL
Data supports LR 09 as a vital checkpoint inhibitor for treating leukaemia patients
